Page 3 - Pharma

Indian companies likely to garner up to 50% USFDA nod share in 2023

Companies may get up to 375 ANDA approvals in 2023, more than last year's 355

Indian pharma firm recalls 27 types of eyedrops in US made for CVS, Walmart

The Food and Drug Administration warned consumers last month not to purchase or use store-brand eyedrops from Walmart Inc., CVS Health Corp., Target Corp. and other companies

Torrent Pharma Q2 results: Profit after tax up 24% to Rs 386 crore

The company exhibited a 2.66 per cent increase in revenue and was able to turn around the PAT by 2.09 per cent

2,350 acres set aside for pharma and medical parks in Uttar Pradesh

Chief Minister Yogi Adityanath has envisioned increasing the state's contribution to the pharma industry from 2 per cent to 10-12 per cent

Valiant Labs freezes at upper circuit on debut; up 22% over issue price

At 10:03 AM; shares of Valiant Labs were locked at the 5 per cent upper circuit at Rs 170.25, up 22 per cent over its issue price of Rs 140 per share.

Natural light may help treat and prevent type 2 diabetes: Research

Exposure to natural light may help treat and prevent type 2 diabetes, according to a small study. The research, presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Germany from October 2-6, carried out a range of metabolic tests on a group of people with type 2 diabetes when they were exposed to natural light and when they were exposed to artificial light and compared the results. "The misalignment of our internal circadian clock with the demands of a 24/7 society is associated with an increased incidence of metabolic diseases, including type 2 diabetes," said Ivo Habets of Maastricht University, the Netherlands, who co-led the research. "Natural daylight is the strongest zeitgeber, or environmental cue, of the circadian clock, but most people are indoors during the day and so under constant artificial lighting," said Habets. The yet-to-be peer-reviewed study involved 13 participants with an average age of 70 years who stayed in research

Glenmark announces license agreements for Winlevi in Europe and S Africa

Cassiopea, a subsidiary of Cosmo, will receive an upfront payment of $5 million and agreed double-digit royalties on net sales

Govt rolls out Rs 5,000 cr scheme for innovation in pharma, medtech

The PRIP scheme has two main components - the first one would focus on infrastructure building

After drive against spurious drugs, DCGI collating data on pharma plants

The DCGI, in a letter dated September 4, has instructed state drug controllers to obtain the details from the firms under their jurisdiction

G20 meet: 3 private hospitals among 8 medical facilities put on high alert

Five government hospitals and three private medical facilities have been put on "high alert" in view of the upcoming G20 Summit in the national capital, Delhi Health Minister Saurabh Bharadwaj has said. The Delhi health department has formed 80 teams of doctors and nursing staff, who will serve guests staying at hotels. Out of these teams, 75 teams will work in shifts, officials said on Wednesday. Bharadwaj convened a meeting at the Delhi Secretariat to take stock of healthcare arrangements in view of the Summit scheduled to be held from September 9 to 10. "In light of the G20 Summit, the Delhi government has placed five major government hospitals and three private hospitals on high alert to ensure the healthcare arrangements are in place. These include primarily Lok Nayak Hospital, GB Pant Hospital, GTB Hospital, Deen Dayal Upadhyay Hospital, and Babasaheb Ambedkar Hospital, along with private facilities Primus Hospital Chanakyapuri, Max Hospital Saket, and Manipal Hospital Dwarka,

Top headlines: Pharma likely to take 5-6% price hikes, FDI outflow soars

Business Standard brings the top headlines at this hour

Lupin gets USFDA approval to market generic skin treatment medication

Lupin on Wednesday said its American subsidiary has received an approval from the US health regulator to market a generic product used for treatment of skin issues. New Jersey-based Novel Laboratories Inc has received the approval from the US Food and Drug Administration (USFDA) for Fluocinolone Acetonide Topical Oil, Lupin said in a statement. The product is the generic version of Hill Dermaceuticals Inc's Derma-Smoothe/FS Topical Oil. Lupin said the product will be manufactured at its Somerset facility in the US. As per the IQVIA MAT March 2023 data, Fluocinolone Acetonide Topical Oil had estimated annual sales of USD 9 million in the US. Lupin shares were trading 0.67 per cent down at Rs 981.65 apiece on the BSE.

Global abortion pill provider buys from Indian firm with bad quality record

More than 30 samples of drugs made by Delhi-based Synokem Pharmaceuticals Ltd have failed quality tests conducted by Indian regulators

Double-digit price erosion in the US generic market is getting arrested.

After a poor run in 2022, Pharma and healthcare funds are up 22.4 per cent year-to-date. The fundamental reason behind this upsurge is the improving outlook of the US generic market, says Mr. Chirag

India pharma exports surging despite cough syrup deaths: Trade body

Two other cough syrups made in India killed 19 children in Uzbekistan around December, according to the Uzbekistan government

1 drug sample spurious and nearly 48 substandard in June inspection

Eye-drops made by Indiana Ophthalmics in Gujarat that have been under the scanner also feature in the list

Explained: Toxic cough syrups and India's pharma oversight

A devastating outbreak in Gambia claimed the lives of 60 kids. Tests conducted by WHO revealed that the cause was toxic industrial solvents found in cheap,over-the-counter syrups made by Maiden Pharma

Top Headlines: Lapses in pharma regulation, IPL's valuation rises 80%

Business Standard brings you the top headlines at this hour

Neuro feedback devices that read your mind are here

Mind-reading devices read the movement of pupils, heart rates and brain impulses. They will be able to predict human movement, action and thought

AstraZeneca announces launch of cancer medication Tremelimumab in UAE

AstraZeneca has announced the launch of its revolutionary cancer medication, IMJUDO (tremelimumab) in the UAE